Primary or Early Triple Negative Breast Cancer

This section is intended for those people diagnosed with TNBC with no sign that it has spread away from the breast and lymph glands nearby into other organs.

This is called primary or early stage breast cancer, and in many people it can be cured. 

We hope this will help you to understand your treatment options, ask questions to your medical team and cope with the physical and emotional pressures.

What decides how my cancer will be treated?

There are similarities but also differences between TNBC and other types of breast cancer. That means that some, but not all, of your treatments and experiences will be different to those of  people with other types of breast cancer.

When TNBC is caught early it can be successfully treated and often cured by a mixture of surgery, radiotherapy and drug treatment.

You will probably already have had a ‘biopsy’, where a small part of the breast lump was taken out using a needle, to see whether it was cancer, and if so, what sort of cancer. You may also have X-rays, scans and blood tests.

Your surgeon and oncologist (cancer doctor) will recommend the best treatment for you depending on the results of these tests and in particular:

  • The size of the cancer, usually ranked 1, 2 or 3

  • It’s grade, which is how nasty or “aggressive” the cancer cells look under the microscope; this is graded 1, 2 or 3 (with grade 3 the most aggressive)

  • Whether the cancer has spread to the lymph glands in the armpit (or axilla)

What are the main treatments for TNBC?

Treatment for TNBC that has not spread is usually a mix  of surgery, with or without radiotherapy, and drug treatment. While surgery and radiotherapy, the ‘local’ treatments to treat the cancer in your breast are the same as for other types of breast cancer, the drug treatments are different for people with TNBC.

What chemotherapy will I be offered?

The chemotherapy drugs you will receive are used in people with a wide variety of cancers, including other types of breast cancer. These include paclitaxel often given with carboplatin, which may  work better against TNBC, epirubicin and cyclophosphamide.

Most chemotherapy is given intravenously directly into a vein, usually in your hand, often every 3 weeks, but sometimes weekly. Treatment that would usually be given every 3 weeks is sometimes given every 2 weeks as “accelerated chemotherapy”. This is given with “growth factors”, drugs given as an injection under the skin on the days after chemotherapy that largely prevent the fall in the number of white blood cells, and associated increased risk of infection, that would otherwise happen.

Another chemotherapy drug, called capecitabine, is a tablet taken by mouth. Capecitabine is usually given to people with TNBC who had other chemotherapy before their operation but still had some cancer present in the breast or lymph gland after that chemotherapy.

Chemotherapy are strong drugs and do have side effects, but these are well known and can usually be controlled. Whether you get side effects, and how bad they are, differs from person to person. Your oncology team will provide you with detailed information about side effects of the particular chemotherapy drugs that you are to receive. You may want to keep notes of any side effects so you can discuss them with your medical team at your next appointment.

A nurse fits an intravenous drip for an older female patient sat comfortably in a chair in a doctor's office. Behind the patient is medical equipment

Will I be offered immunotherapy?

Recently, clinical trials have shown that some people with early TNBC benefit from the addition of immunotherapy, which stimulates the immune system.

Pembrolizumab (Keytruda) is a targeted therapy that helps the immune system “see” and attack cancer cels by blocking a chemical that cancer cells use to hide. It may be considered in people with early TNBC at higher risk of their cancer returning and spreading.

Pembrolizumab is given intravenously, with chemotherapy, before surgery and then for a year after surgery. It has side effects that result from the immune system also attacking normal parts of the body such as the gut, lungs or thyroid gland and you will be monitored closely while taking pembrolizumab.

What other drugs might I be offered?

Your oncologists may also discuss other, targeted drugs, which are not chemotherapy or immunotherapy, after surgery.

Bisphosphonates are drugs that strengthen the bones, but can also reduce the risk of breast cancer coming back in women who are postmenopausal. The bisphosphonate can be taken by mouth daily for 3 – 5 years but can cause irritation of the gullet or oesophagus. If taken intravenously, the bisphosphonate is typically given every 6 months. When you start the bisphosphonate, you will have your vitamin D levels checked and you may need to take supplements if youR vitamin D levels are low. Bisphosphonates can also cause problems with healing of the jaw after having a tooth removed, something called osteonecrosis of the jaw. For this reason you will be advised to have a dental check-up and, any treatment dental treatment completed, before starting the bisphosphonate. If you see your dentist when you are taking a bisphosphonate, you should tell them.

Finally, breast cancer in people with BRCA 1 or BRCA2 mutations (which can be inherited) is more commonly TNBC than other types of breast cancer. For people with BRCA mutated TNBC who are at higher risk of the cancer coming back, that risk can be reduced by taking the tablet olaparib (or Lynparza) for a year after completing chemotherapy. Again, this is a targeted therapy, and often referred to as a PARP inhibitor because of how it works. Although not chemotherapy, olaparib can have significant side effects.

Will I receive these drugs before or after surgery?

In the past, drug treatment always followed surgery and was known as adjuvant treatment. These days, drug treatment is often given before surgery and known as neo-adjuvant therapy. Your cancer team will discuss with you what is best for you and what you prefer.

Having neo-adjuvant treatment, before surgery, means the cancer can be monitored and measured to see whether treatment is working. This treatment can also affect the type of surgery that is then needed. Finally, if cancer cells can still be seen in the specimen removed at surgery, this can affect whether further drug treatment is discussed.

Neo-adjuvant chemotherapy usually lasts 12-24 weeks and in some people is given with immunotherapy.

Adjuvant chemotherapy is given to people who did not receive neo-adjuvant therapy; in this situation adjuvant chemotherapy is with the same or similar drugs that are used as neo-adjuvant treatment. Other adjuvant treatment can also be given in the form of: 

  • Pembrolizumab given for a year after surgery and neo-adjuvant immunotherapy (and chemotherapy)

  • Capecitabine for 6 months offered to people in whom cancer can be seen in the tissue removed at surgery after neo-adjuvant treatment.

  • Olaparib for a year considered for people with BRCA1 or 2 mutations

New treatments are being developed for people with early or primary TNBC and you might want to ask your medical team about clinical trials. Please see the section Trials, Research and Donationsfor more details.

What can I do to help my recovery?

There is a lot of evidence that staying positive, fit and healthy can help with your recovery.

Ignore ‘myths’ on the internet and use only authoritative and reliable sources of information such as The UK Charity for TNBC, MacMillan Cancer Relief and Cancer Research UK.

An older black woman wearing a grey vest top in the gym on a cycling exercise machine. The woman is smiling, enjoying her time. These is a woman in the background also working out.

Frequently asked questions about early stage/primary TNBC